Close Menu

NEW YORK (GenomeWeb) – Cowen has initiated coverage on Horizon Discovery Group with an Outperform rating and a £2.90 ($3.73) price target.

In a research note, Cowen's Doug Schenkel noted that Horizon has "quickly evolved into an emerging leader in gene editing life science tools," especially in the wake of the company's July acquisition of Dharmacon from GE.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.